Samik Pharm삼익제약
014950 · KOSDAQ · ₩014950 · 삼익제약
Valuation model · Discounted cash flow (DCF)
We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.
Fair value per share
₩4,805
vs the current price (₩7,690)
- Enterprise value
- ₩21B
- Equity value
- ₩48B
- WACC
- 7.4%
Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.
Why the model and the price differ
The model is 38% away from today's price. A gap this size usually means the market expects something the past figures don't show yet, or the model leaves something out. What we can see:
- To match today's price of ₩7,690, the model needs an operating margin of 7.5% every year (it uses 4.2%).
Treat the model as a starting point: change the assumptions to the story you believe, and compare with the multiples check below.
Bear / Base / Bull
- Bear
- ₩3,159
- −58.9%
- Base
- ₩4,805
- −37.5%
- Bull
- ₩7,893
- +2.6%
Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.
Assumptions
Sign in to change the assumptions and see the results update. Sign in
Cycle options
Margin path
Every year uses the cycle-average margin (4.2%).
Revenue growth
- 3%
How much sales grow that year, compared with the year before.
Default: not enough revenue history, so 3%.
- 3%
How much sales grow that year, compared with the year before.
Default: not enough revenue history, so 3%.
- 3%
How much sales grow that year, compared with the year before.
Default: not enough revenue history, so 3%.
- 3%
How much sales grow that year, compared with the year before.
Default: not enough revenue history, so 3%.
- 3%
How much sales grow that year, compared with the year before.
Default: not enough revenue history, so 3%.
Business
- 4.2%
Operating profit as a share of revenue.
Default: through-the-cycle average of the last 12 months and the last 1 annual reports' operating margins.
- 27.5%
Share of operating profit paid as corporate tax.
Default: Korea's top corporate tax rate (25%) plus 10% local income tax.
- 4.6%
The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).
Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).
- 5.7%
Money spent on factories, equipment, software and other long-term assets (% of revenue).
Default: average of the last 1 annual reports (cash flow statements; equipment and intangibles).
- 32.8%
Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.
Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 1 years.
Discount rate
- 2%
How fast cash flows keep growing every year after year 5.
Default: about Korea's long-run inflation plus real growth.
- 4.08%
Yield on Korea's 10-year government bond: the return with almost no risk.
Default: Korea Treasury Bond 10-year yield on 2026-10-29.
- 0.61
How much the share moves when the market moves: 1 means just like the market.
Default: 52 weeks of weekly returns against KOSPI (official index); raw beta 0.41, adjusted toward 1 and kept between 0.6 and 2.0.
- 5.5%
The extra return investors want for owning shares instead of bonds.
Default: a typical premium for Korean shares.
- 5.58%
The interest rate the company would pay to borrow.
Default: the 10-year yield plus a 1.5% credit spread.
Starting point
- Revenue (TTM to H1 2026)
- ₩62B
- Net debt (borrowings and leases − cash and deposits)
- −₩27B
- + Stakes and investments
- ₩5.5M
- Associates, long-term financial assets and deposits (book value)
- Shares
- 10,087,588
- Share price
- ₩7,690
- Market cap
- ₩78B
TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.
Past years and projection
Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.
| FY2025 | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|---|
| Revenue | ₩60B | ₩64B | ₩66B | ₩68B | ₩70B | ₩72B |
| Growth | — | 3.0% | 3.0% | 3.0% | 3.0% | 3.0% |
| EBIT | ₩3.3B | ₩2.7B | ₩2.8B | ₩2.9B | ₩2.9B | ₩3B |
| EBIT margin | 5.5% | 4.2% | 4.2% | 4.2% | 4.2% | 4.2% |
| After-tax EBIT | ₩2.4B | ₩2B | ₩2B | ₩2.1B | ₩2.1B | ₩2.2B |
| + Depreciation | — | ₩2.9B | ₩3B | ₩3.1B | ₩3.2B | ₩3.3B |
| − Capital spending | ₩3.4B | ₩3.7B | ₩3.8B | ₩3.9B | ₩4B | ₩4.1B |
| − Working capital | — | ₩613M | ₩631M | ₩650M | ₩669M | ₩690M |
| Free cash flow | — | ₩635M | ₩654M | ₩673M | ₩694M | ₩714M |
| Discount factor | — | 0.931 | 0.866 | 0.806 | 0.751 | 0.699 |
| Present value | — | ₩591M | ₩566M | ₩543M | ₩521M | ₩499M |
Terminal value ₩26B, worth ₩18B today: 87% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.
Sensitivity
Fair value per share as two inputs change; the middle is the current case.
| WACC ↓ · Terminal growth → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 6.4% | ₩5,199 | ₩5,257 | ₩5,326 | ₩5,410 | ₩5,517 |
| 6.9% | ₩4,964 | ₩4,999 | ₩5,039 | ₩5,086 | ₩5,143 |
| 7.4% | ₩4,766 | ₩4,784 | ₩4,805 | ₩4,827 | ₩4,853 |
| 7.9% | ₩4,597 | ₩4,604 | ₩4,611 | ₩4,617 | ₩4,623 |
| 8.4% | ₩4,451 | ₩4,450 | ₩4,447 | ₩4,443 | ₩4,436 |
Now (TTM)
- Market cap
- ₩78B
- Enterprise value
- ₩50B
- P/E
- —
- P/B
- 1.1×
- P/S
- 1.2×
- EV/EBITDA
- —
- Dividend yield
- 0.5%
Over time (at each year end)
| 2025 | |
|---|---|
| Price | ₩13,970 |
| Market cap | ₩141B |
| P/E | — |
| P/B | 2.0× |
| P/S | 2.3× |
| EV/EBITDA | — |
| Dividend yield | 0.3% |
Versus similar companies
| Company | P/E | P/B | P/S | EV/EBITDA | Dividend yield |
|---|---|---|---|---|---|
| Samik Pharm | — | 1.1× | 1.2× | — | 0.5% |
| Samsung Biologics | 32.0× | 7.6× | 14.0× | — | 0.0% |
| Celltrion | 27.9× | 2.5× | 9.0× | — | 0.0% |
| Alteogen | 80.5× | 29.0× | 61.2× | — | 0.1% |
| SK biopharmaceuticals | 14.7× | 5.8× | 6.8× | — | 0.0% |
| Yuhan | 24.0× | 2.4× | 2.5× | 31.3× | 0.8% |
| HLB | — | 15.7× | 55.6× | — | 0.0% |
| Similar companies (median) | 27.9× | 6.7× | 11.5× | 31.3× | 0.0% |
Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.
Also known as: Samik Pharm / 삼익제약 / 014950 / KRX:014950
Source: KRX statistical information